Getinge AB
STO:GETI B
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
165.35
239.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Getinge AB
Getinge AB
Cash & Cash Equivalents
Getinge AB
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Getinge AB
STO:GETI B
|
Cash & Cash Equivalents
kr2.7B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Elekta AB (publ)
STO:EKTA B
|
Cash & Cash Equivalents
kr2.8B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
S
|
Surgical Science Sweden AB
STO:SUS
|
Cash & Cash Equivalents
kr666.3m
|
CAGR 3-Years
29%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
|
CellaVision AB
STO:CEVI
|
Cash & Cash Equivalents
kr137.7m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
9%
|
|
|
Arjo AB (publ)
STO:ARJO B
|
Cash & Cash Equivalents
kr923m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
S
|
Stille AB
STO:STIL
|
Cash & Cash Equivalents
kr97.9m
|
CAGR 3-Years
45%
|
CAGR 5-Years
20%
|
CAGR 10-Years
52%
|
|
Getinge AB
Glance View
Getinge AB is a medical technology company specializes in providing equipment, systems, operating rooms, intensive-care units to the healthcare and the life science industries. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 10,729 full-time employees. The firm provides hospitals and Life Science institutions with products and solutions aimed at improving clinical outcomes and optimizing workflows. The Company’s reporting segments have the following activities: Acute Care Therapies develops solutions for life-sustaining care in acute health conditions. Life Science offers a comprehensive range of equipment, technical expertise and prevention consultation contamination in pharmaceutical production, biomedical research, production of medical equipment and in various laboratory applications. Surgical Workflows offers products and services for the effective disinfection and sterilization of instruments used in operations, operating tables and others hardware for operating rooms and advanced IT systems for efficient and secure workflows in hospitals.
See Also
What is Getinge AB's Cash & Cash Equivalents?
Cash & Cash Equivalents
2.7B
SEK
Based on the financial report for Dec 31, 2023, Getinge AB's Cash & Cash Equivalents amounts to 2.7B SEK.
What is Getinge AB's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
16%
Over the last year, the Cash & Cash Equivalents growth was -52%. The average annual Cash & Cash Equivalents growth rates for Getinge AB have been -23% over the past three years , 16% over the past five years .
You don't have any saved screeners yet
